Hill-Rom Holdings, Inc. (HRC) Given New $75.00 Price Target at Barclays PLC
Hill-Rom Holdings, Inc. (NYSE:HRC) had its price target upped by stock analysts at Barclays PLC from $70.00 to $75.00 in a research report issued to clients and investors on Wednesday. The brokerage presently has an “overweight” rating on the medical technology company’s stock. Barclays PLC’s price objective points to a potential upside of 4.75% from the company’s previous close.
Several other brokerages have also recently weighed in on HRC. Zacks Investment Research upgraded shares of Hill-Rom Holdings from a “hold” rating to a “buy” rating and set a $80.00 price objective for the company in a research note on Monday, April 3rd. Stifel Nicolaus assumed coverage on shares of Hill-Rom Holdings in a research note on Monday, January 23rd. They issued a “buy” rating and a $70.00 price objective for the company. Six research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus target price of $69.17.
Hill-Rom Holdings (NYSE:HRC) traded up 0.79% during midday trading on Wednesday, hitting $71.60. 316,181 shares of the company traded hands. The firm has a market capitalization of $4.68 billion, a PE ratio of 33.35 and a beta of 1.20. Hill-Rom Holdings has a 12-month low of $46.79 and a 12-month high of $71.83. The stock’s 50-day moving average is $69.25 and its 200-day moving average is $61.08.
Hill-Rom Holdings (NYSE:HRC) last issued its quarterly earnings data on Friday, January 27th. The medical technology company reported $0.75 earnings per share for the quarter, hitting the consensus estimate of $0.75. Hill-Rom Holdings had a net margin of 5.44% and a return on equity of 19.12%. The business earned $637.40 million during the quarter, compared to analysts’ expectations of $654.12 million. During the same quarter in the previous year, the company earned $0.68 EPS. The business’s revenue was down 3.7% on a year-over-year basis. Analysts anticipate that Hill-Rom Holdings will post $3.82 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Friday, March 31st. Stockholders of record on Friday, March 24th were given a $0.18 dividend. The ex-dividend date of this dividend was Wednesday, March 22nd. This is a boost from Hill-Rom Holdings’s previous quarterly dividend of $0.17. This represents a $0.72 annualized dividend and a dividend yield of 1.01%. Hill-Rom Holdings’s payout ratio is presently 31.78%.
In other news, CEO John J. Greisch sold 207,987 shares of the business’s stock in a transaction that occurred on Tuesday, March 7th. The shares were sold at an average price of $65.86, for a total value of $13,698,023.82. Following the completion of the transaction, the chief executive officer now directly owns 301,565 shares in the company, valued at approximately $19,861,070.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Paul Sherwood Johnson sold 1,403 shares of the business’s stock in a transaction that occurred on Thursday, February 9th. The shares were sold at an average price of $60.95, for a total transaction of $85,512.85. Following the completion of the transaction, the senior vice president now owns 2,078 shares of the company’s stock, valued at $126,654.10. The disclosure for this sale can be found here. Insiders sold a total of 224,390 shares of company stock valued at $14,823,637 over the last 90 days. Corporate insiders own 2.20% of the company’s stock.
Several institutional investors have recently modified their holdings of HRC. BlackRock Advisors LLC boosted its position in shares of Hill-Rom Holdings by 2.8% in the third quarter. BlackRock Advisors LLC now owns 35,530 shares of the medical technology company’s stock valued at $2,202,000 after buying an additional 984 shares during the last quarter. Americafirst Capital Management LLC purchased a new position in shares of Hill-Rom Holdings during the third quarter valued at approximately $1,799,000. US Bancorp DE boosted its position in shares of Hill-Rom Holdings by 0.6% in the third quarter. US Bancorp DE now owns 4,612 shares of the medical technology company’s stock valued at $285,000 after buying an additional 28 shares during the last quarter. UBS Asset Management Americas Inc. boosted its position in shares of Hill-Rom Holdings by 98.2% in the third quarter. UBS Asset Management Americas Inc. now owns 107,813 shares of the medical technology company’s stock valued at $6,681,000 after buying an additional 53,425 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Hill-Rom Holdings by 3.3% in the third quarter. Bank of New York Mellon Corp now owns 719,371 shares of the medical technology company’s stock valued at $44,588,000 after buying an additional 22,930 shares during the last quarter. Institutional investors own 83.53% of the company’s stock.
Hill-Rom Holdings Company Profile
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
Receive News & Ratings for Hill-Rom Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.